JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.17 -0.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.16

Максимум

1.2

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+152.1% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-29M 73M
Предишно отваряне	2.02
Предишно затваряне	1.17

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 23:11 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting All-Time High -- Market Talk

3.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

3.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3.02.2026 г., 23:38 ч. UTC

Печалби

AMD Sales Climb on Help From Data-Center Business -- Update

3.02.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3.02.2026 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3.02.2026 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3.02.2026 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.02.2026 г., 22:56 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3.02.2026 г., 22:40 ч. UTC

Печалби

Amdocs Extends Collaboration With T-Mobile

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Adj EPS $1.81

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Rev $1.16B

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q EPS $1.45 >

3.02.2026 г., 22:38 ч. UTC

Печалби

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3.02.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3.02.2026 г., 22:14 ч. UTC

Печалби

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3.02.2026 г., 22:13 ч. UTC

Печалби

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3.02.2026 г., 22:12 ч. UTC

Печалби

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3.02.2026 г., 22:10 ч. UTC

Печалби

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3.02.2026 г., 22:10 ч. UTC

Пазарно говорене

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

152.1% нагоре

12-месечна прогноза

Среден 3 USD 152.1%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.